← back to search

Daniel Durocher

University of New Brunswick · CA
Area of research
Molecular Biology · Oncology
Research interest
Research interests include DNA Repair Mechanisms, CRISPR and Genetic Engineering, Ubiquitin and proteasome pathways, and Genomics and Chromatin Dynamics.
h-index
76
citations
30,044
works
203
NIH funding
primary concept
Biology
email

Recent publications

Design of a Targeted Covalent Probe to Interrogate the DNA Polymerase Activity of Polθ.
2026cited by 0position: contributordoi
CRISPR-enabled genetic screens identify synthetic lethal targets across frequently altered cancer drivers
2026cited by 0position: contributordoi
Synthetic lethal strategies for the development of cancer therapeutics.
2025cited by 32position: contributordoi
Rewiring DNA repair with PARP-based chemical inducers of proximity
2025cited by 2position: contributordoi
WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response
2025cited by 1position: contributordoi
Mitotic single-stranded DNA suppression by DDIAS
2025cited by 1position: contributordoi
Author Correction: PP4 is a γH2AX phosphatase required for recovery from the DNA damage checkpoint.
2025cited by 0position: contributordoi
Author Correction: A substrate binding model for the KEOPS tRNA modifying complex.
2025cited by 0position: contributordoi
WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response.
2025cited by 0position: contributordoi
Author Correction: A substrate binding model for the KEOPS tRNA modifying complex
Nature Communications 2025cited by 0position: middledoi
Synthetic lethal strategies for the development of cancer therapeutics
Nature Reviews Clinical Oncology 2024cited by 53position: middledoi
Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.
2024cited by 19position: contributordoi
Profound synthetic lethality between SMARCAL1 and FANCM
Molecular Cell 2024cited by 15position: contributordoi
NFATC2IP is a mediator of SUMO-dependent genome integrity.
2024cited by 10position: contributordoi
Profound synthetic lethality between SMARCAL1 and FANCM
2024cited by 1position: contributordoi
An AlphaFold2 map of the 53BP1 pathway identifies a direct SHLD3-RIF1 interaction critical for shieldin activity.
2023cited by 26position: contributordoi
Functional characterization of C21ORF2 association with the NEK1 kinase mutated in human in diseases
Life Science Alliance 2023cited by 21position: middledoi
Genome-scale mapping of DNA damage suppressors through phenotypic CRISPR-Cas9 screens.
2023cited by 18position: contributordoi
Functional characterization of C21ORF2 association with the NEK1 kinase mutated in human in diseases.
2023cited by 15position: contributordoi
A mitotic glue for shattered chromosomes.
2023cited by 3position: contributordoi
An AlphaFold2 map of the 53BP1 pathway identifies a direct SHLD3-RIF1 interaction critical for DNA repair activity
2023cited by 2position: contributordoi
Chemogenetic profiling of ubiquitin-like modifier pathways identifies NFATC2IP as a mediator of SUMO-dependent genome integrity
2023cited by 0position: contributordoi
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
2022cited by 180position: contributordoi
The CIP2A-TOPBP1 complex safeguards chromosomal stability during mitosis.
2022cited by 53position: contributordoi
RIF1 acts in DNA repair through phosphopeptide recognition of 53BP1
Molecular Cell 2022cited by 43position: contributordoi
Global cellular response to chemical perturbation of PLK4 activity and abnormal centrosome number.
2022cited by 10position: contributordoi
Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability
2022cited by 6position: contributordoi
Interaction with C21ORF2 controls the cellular functioning of the NEK1 kinase
2022cited by 0position: contributordoi
Author Reply to Peer Reviews of Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability
2022cited by 0position: contributordoi
Genome-scale mapping of DNA damage suppressors identifies GNB1L as essential for ATM and ATR biogenesis
2022cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 49 papers (2019–2026)Lisa Hoeg · Lunenfeld-Tanenbaum Research Institute7 papers (2023–2025)Anne-Claude Gingras · University of Toronto7 papers (2020–2026)Frank Sicheri · Mount Sinai Hospital6 papers (2020–2026)Dheva T Setiaputra · Mount Sinai Hospital6 papers (2022–2025) · 4 papers (2013–2023)Johnny M. Tkach · Sinai Health System4 papers (2021–2022)Jason Moffat · University College London4 papers (2021–2024)Leo C. K. Wan · Hospital for Sick Children3 papers (2017–2025)Yiqing Lu · Ministry of Ecology and Environment3 papers (2022–2024) · 3 papers (2019–2024)Pierre Maisonneuve · Mount Sinai Hospital3 papers (2020–2025)Daniel Schramek · Amgen (Canada)3 papers (2022–2024)Derek Ceccarelli · Lunenfeld-Tanenbaum Research Institute3 papers (2020–2025)Manuel Stucki · University of Zurich3 papers (2021–2022)Sylvie M. Noordermeer · Leiden University Medical Center3 papers (2021–2021)Yibo Xue · Princess Margaret Cancer Centre3 papers (2021–2025)Moshe Oren · National Center for Tumor Diseases3 papers (2022–2024)Alexandre Orthwein · Emory University3 papers (2013–2017)Amélie Fradet‐Turcotte · Université Laval3 papers (2013–2017)